Angle PLC's Parsortix: Revolutionizing Cancer Treatment and Clinical Trials

Angle PLC (AGL.L), a world-leading liquid biopsy company, has announced that its innovative Parsortix system has been used in a groundbreaking research paper from ETH Zurich. The Parsortix system, which captures live, intact circulating tumor cells (CTCs) and CTC clusters from whole blood, played a critical role in selecting patients for a targeted treatment in a clinical trial. This development has significant implications for clinical trial design, drug development, and patient outcomes.

The Parsortix system was used to identify patients with highly metastatic CTC clusters in a Phase 1 clinical trial using the repurposed, FDA-approved drug digoxin to treat metastatic breast cancer patients. The trial successfully achieved its primary endpoint, with a significant reduction in CTC cluster size reported in the treatment group. This proof-of-principle study paves the way for the development of a novel class of drugs that prevent or suppress the development of metastasis.

The use of the Parsortix system in identifying CTC clusters has a substantial impact on the selection of patients for targeted treatments. By enabling researchers to enroll only those patients who might benefit from digoxin treatment, the Parsortix system helps improve the success rate of clinical trials and accelerates the development of novel drugs targeting the metastatic cascade. Additionally, the system allows for continuous monitoring to determine the pharmacodynamic effects of drugs, providing valuable insights into the efficacy and safety of new treatments.

The reduction in CTC cluster size reported in the treatment group is a significant finding, as it demonstrates the potential of digoxin to dissociate highly metastatic CTC clusters in metastatic breast cancer patients. This reduction in CTC cluster size could translate to improved patient outcomes in several ways, including enhanced immune response, increased effectiveness of existing treatments, reduced metastatic spread, and better patient selection.

The collaboration between ANGLE plc, ETH Zurich, and PAGE Therapeutics is enhancing the development of novel compounds targeting metastatic spread by leveraging the unique capabilities of the Parsortix system. The Parsortix system plays a crucial role in selecting patients who are positive for CTC clusters, enabling the enrollment of patients most likely to benefit from targeted treatments. Additionally, the system allows for continuous monitoring of CTC clusters, enabling researchers to determine the pharmacodynamic effects of novel compounds and optimize dosing. The Parsortix system is anticipated to play a crucial role in the pre-clinical and clinical development of novel compounds by PAGE Therapeutics, including dose finding and selection of the most appropriate patients for clinical trials.

The potential market opportunities for these treatments are significant, given that the spread of cancer accounts for the vast majority of cancer-related deaths. The effective prevention and suppression of metastasis is an elusive goal for clinicians worldwide, presenting an uncharted opportunity for the development of targeted agents that disrupt the causes of metastasis themselves. With the global cancer market expected to reach $200 billion by 2025, novel treatments targeting the metastatic process could represent a substantial market opportunity.



In conclusion, Angle PLC's Parsortix system is revolutionizing cancer treatment and clinical trials by enabling targeted patient selection, improving the success rate of trials, and providing valuable insights into the efficacy and safety of new treatments. The collaboration between ANGLE plc, ETH Zurich, and PAGE Therapeutics is enhancing the development of novel compounds targeting metastatic spread, with significant market opportunities for these treatments.